Bio-Rad Laboratories, Inc. (NYSE:BIO) reported Q2 2017 earnings this Afternoon, coming in at $0.39 per share, missing Wall Street’s estimates of $0.56 per Share. Revenue for the quarter came in at $504.70 million missing the streets estimates of $515.69 million
Analyst Coverage For Bio-Rad Laboratories, Inc. (NYSE:BIO)
These are 4 Buy Ratings .
The current consensus rating for Bio-Rad Laboratories, Inc. (NYSE:BIO) is Buy (Score: 3.00) with a consensus target price of $225.00 , a potential (7.13% downside)Recent Insider Trading for Bio-Rad Laboratories, Inc. (NYSE:BIO)
- On 3/7/2017 Michael Crowley, EVP, sold 300 with an average share price of $196.13 per share and the total transaction amounting to $58,839.00.
- On 11/9/2016 James R. Stark, VP, sold 1,299 with an average share price of $171.42 per share and the total transaction amounting to $222,674.58.
Recent Trading for Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares of Bio-Rad Laboratories, Inc. closed the previous trading session at 242.28 up +3.68 1.54% with 111,516 shares trading hands.